A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

This early-phase clinical trial studies BGB-B455, a new type of cancer immunotherapy drug called a bispecific antibody, in adults with advanced or metastatic solid tumors that express a protein called claudin 6 (CLDN6) on their tumor cells. The drug is designed to connect CLDN6-positive cancer cells with immune T cells to trigger a targeted immune attack against the tumor. Adults with advanced solid tumors who have already received standard treatments (or for whom no standard treatment is available), have good functional status, and whose tumors test positive for CLDN6 may be eligible. Participation involves receiving BGB-B455 infusions either alone or in combination with chemotherapy, with the main goals being to determine a safe and effective dose and to monitor for side effects. This summary was generated with AI assistance to help patients understand the study in plain language.